Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 2, 1998

View Archived Issues

Techniclone advancing development of Tumor Necrosis Therapy into phase II

PEG-hirudin more effective than heparin in patients with acute coronary syndromes

Hemosol blood substitute to enter phase II clinical trials in U.S. for CABG

AEterna isolates molecule exhibiting anti-MMP activity

Positive results reported from clinical trial of Remune

SNAP-8719: a valuable tool for studying alpha1D-adrenoceptor function

Xoma: Q2 1998 highlights

Medarex receives milestone payment from Merck KGaA

Novartis announces VALIANT trial

CAT demonstrates value of ProxiMol technology

AnorMED initiates phase I clinical trial of AMD-3100

Betaseron to receive fast track review in Canada

Lamotrigine approved for new indication in the U.S.: Lennox-Gastaut syndrome

Cambridge NeuroScience announces advances in MS program

AutoImmune: Q2 1998 highlights

P&U to market Glyset in U.S., Canada and several other countries

Phase I/II trial provides evidence of potential efficacy of ovarian cancer vaccine

Potent new antimalarial trioxanes developed at Johns Hopkins

L-168721: potent, nonpeptide GH secretagogue

Novartis describes search for potent and selective CDK1/CDK2 inhibitors

Lead candidate for botulinum neurotoxin poisoning: ICD-1578

Banyu presents urea derivatives with NPY receptor-antagonist activity

Inhibitors of NOS developed at Pfizer

Anticonvulsant benzamides prepared at SKB

Zeneca patents new peptides for autoimmune/inflammatory disorders

Merck & Co. claims glucagon antagonists, cytokine inhibitors

Compounds interacting with nicotinic receptors for cognitive and memory deficits

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...